Stumping for stem cells

The linkurl:California stem cell policy and advocacy juggernaut;http://www.the-scientist.com/news/display/23097/ was in full steam this weekend at Stanford University. The two-day linkurl:Stem Cell Policy and Advocacy Summit II: Empowering the Pro-Cures Coalition;http://www.pro-cures.com offered a banquet of the usual servings, including scientific updates, discussions of linkurl:ethics;http://www.the-scientist.com/blog/display/23251/ and legal issues, and how-to primers on grassroots advocacy.

Written byCatherine Magill
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share
The linkurl:California stem cell policy and advocacy juggernaut;http://www.the-scientist.com/news/display/23097/ was in full steam this weekend at Stanford University. The two-day linkurl:Stem Cell Policy and Advocacy Summit II: Empowering the Pro-Cures Coalition;http://www.pro-cures.com offered a banquet of the usual servings, including scientific updates, discussions of linkurl:ethics;http://www.the-scientist.com/blog/display/23251/ and legal issues, and how-to primers on grassroots advocacy. There was some different fare, however:-- A variety of nationwide polls (e.g., linkurl:Center for the Advancement of Medical Research;http://www.camradvocacy.org/camr_news.aspx?rid=051606B and linkurl:The Genetics and Public Policy Institute;http://www.dnapolicy.org/pub.reports.php?action=detail&report_id=1)have reported that the public supports somatic cell nuclear transfer by approximately 65-70%. That should be good news, but instead Governor Jim Doyle (Wis.) and others said this is evidence of the focus, organization and powerful voice of the 25% opposing it, and should be a rallying cry for supporters. Proposals to counter this force included opening up laboratories for visitation by the public on a monthly or quarterly basis to educate the public on their research. -- The public's lack of understanding of the science behind the research was highlighted during a talk by Stephen Levick, professor of psychiatry at the University of Pennsylvania School of Medicine, on Sunday when he noted that Irv Weissman had recently asked several people to draw a picture of a blastocyst; each of the respondents drew a fetus.-- Bob Klein, chairman of the California Institute of Regenerative Medicine and a major force behind California's Prop. 71, claimed that even minor overall savings that are foreseen to arise from human embryonic stem cell research applied to linkurl:better treatments for chronic diseases;http://www.the-scientist.com/blog/display/23262/ could save significant amounts of money within the US health care system. By his calculations, a 2% cost savings in 6 out of 70 conditions thought to be good targets for therapies from the research would result in a 200% payback on California's Proposition 71 investment. For context, Klein pointed out that $100 billion was saved in the costs of housing of polio victims after Jonas Salk developed the polio vaccine in 1952 and after the first successful big trial of the vaccine in 1955.
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

Share
Illustration of a developing fetus surrounded by a clear fluid with a subtle yellow tinge, representing amniotic fluid.
January 2026

What Is the Amniotic Fluid Composed of?

The liquid world of fetal development provides a rich source of nutrition and protection tailored to meet the needs of the growing fetus.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies

Parse Logo

Parse Biosciences and Graph Therapeutics Partner to Build Large Functional Immune Perturbation Atlas

Sino Biological Logo

Sino Biological's Launch of SwiftFluo® TR-FRET Kits Pioneers a New Era in High-Throughout Kinase Inhibitor Screening

SPT Labtech Logo

SPT Labtech enables automated Twist Bioscience NGS library preparation workflows on SPT's firefly platform